Skip to main content
OpenTrials

Clinical trial condition

Lung Neoplasms

Explore clinical trials studying Lung Neoplasms. Study availability and eligibility vary by location and protocol.

3,668 public trials 792 recruiting studies
Refine in advanced search Browse all conditions

Lung Neoplasms trial results

Active, Not Recruiting

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

NCT05450692

Conditions
Advanced or Metastatic Non-small Cell Lung Cancer, Bronchial Neoplasms, Carcinoma, Bronchogenic, +8 more
Locations
  • Research Site Mobile, Alabama, United States
  • Research Site Chandler, Arizona, United States
  • Research Site Los Alamitos, California, United States
  • Research Site Los Angeles, California, United States
View all 191 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

NCT04092283

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +13 more
Locations
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 831 locations
View Trial Details
Active, Not Recruiting

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

NCT06635824

Conditions
Lung Diseases, Lung Neoplasms, Neoplasms, +5 more
Locations
  • Arizona Blood and Cancer Specialists Tucson, Arizona, United States
  • Usc Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Kaiser Permanente Vallejo Medical Center Vallejo, California, United States
  • Ocala Oncology Center P.L. Ocala, Florida, United States
View all 247 locations
View Trial Details
Active, Not Recruiting

A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

NCT03567642

Conditions
Lung Cancer, Lung Diseases, Lung Neoplasms, +5 more
Locations
  • Memorial Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack Commack, New York, United States
View Trial Details
Active, Not Recruiting

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

NCT05887492

Conditions
Adenocarcinoma, Adenocarcinoma of Lung, Bronchial Neoplasms, +16 more
Locations
  • UCLA Hematology/Oncology Santa Monica, California, United States
  • SCRI at HealthOne Denver, Colorado, United States
  • Florida Cancer Specialists Sarasota, Florida, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View all 13 locations
View Trial Details
Active, Not Recruiting

Screening for High Frequency Malignant Disease

NCT05117840

Conditions
Lung Cancer, Lung Diseases, Lung Neoplasms, +5 more
Locations
  • University of Alabama Birmingham Lung Health Center Birmingham, Alabama, United States
  • Highlands Oncology Group PA Fayetteville, Arkansas, United States
  • Pacific Cancer Medical Center Anaheim, California, United States
  • Providence St. Joseph Hospital Eureka Cancer Program Eureka, California, United States
View all 143 locations
View Trial Details
Active, Not Recruiting

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

NCT05445843

Conditions
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation, Lung Diseases, Lung Neoplasms, +5 more
Locations
  • The Brown University Oncology Group Providence, Rhode Island, United States
  • Novartis Investigative Site Pilar, Buenos Aires, Argentina
  • Novartis Investigative Site Córdoba, Córdoba Province, Argentina
  • Novartis Investigative Site Buenos Aires, Argentina
View all 45 locations
View Trial Details

Related conditions